Haemonetics Corporation

$70.09
(as of Jun 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Haemonetics Corporation

Stock Price
$70.09
Ticker Symbol
HAE
Exchange
NYSE

Industry Information for Haemonetics Corporation

Sector
Healthcare
Industry
Medical Devices

Company Description for Haemonetics Corporation

Country
USA
Full Time Employees
3,023

Haemonetics Corporation, a medical technology company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tool. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Fundamentals for Haemonetics Corporation

Market Capitalization
$3,428,220,928
EBITDA
$355,985,984
Dividends per Share
P/E Ratio
21.18
Forward P/E Ratio
14.47
Earnings per Share
$3.31
Earnings per Share Estimate Next Year
Profit Margin
12.32%
Shares Outstanding
48,041,200
Percent Owned by Insiders
1.11%
Percent Owned by Institutions
118.49%
52-Week High
52-Week Low

Technical Indicators for Haemonetics Corporation

50-Day Moving Average
200-Day Moving Average
RSI
57.39
1.71

Analyst Ratings for Haemonetics Corporation

Strong Buy
3
Buy
5
Hold
1
Sell
1
Strong Sell
0

News About Haemonetics Corporation

Jun 11, 2025, 11:34 PM EST
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. See more.
Jun 9, 2025, 12:31 AM EST
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. See more.
Jun 5, 2025, 7:56 AM EST
Blood products company Haemonetics (NYSE:HAE). announced better-than-expected revenue in Q1 CY2025, but sales fell by 3.7% year on year to $330.6 million. See more.
Jun 4, 2025, 12:34 AM EST
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. See more.